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INTRODUCTION 
 
Hepatitis E virus (HEV) infection is a major public health problem in several developing 
countries of the world, especially the Indian sub-continent, South East and Central Asia, 
where it is endemic.1,2,3 HEV in endemic regions not only causes large epidemics but is 
also responsible for a significant proportion of acute sporadic hepatitis in both children 
and adults. In India, HEV infection alone has been shown to account for 50-70% of all 
episodes of sporadic viral hepatitis.4,5  It has been suggested that HEV is more widespread 
than previously believed, prompting the World Health Organization to label HEV as an 
“emerging pathogen”. 
 
Acute HEV infection is generally a self limiting illness similar to other forms of acute 
viral hepatitis, except in pregnant women in whom the illness is particularly severe with a 
high mortality rate.6,7,8 Accumulating evidence indicates that HEV infection may be 
associated with severe liver disease in certain other settings also, namely, concomitant 
HEV and HAV infection in children9, acute liver failure in the sporadic setup10 and 
superinfection on preexisting chronic liver disease (CLD).11,12,13,14,15 Therefore the 
disease burden of HEV in the developing world is heavy as it causes substantial 
morbidity, mortality and economic loss.16 
 
Acute on chronic liver failure (ACLF) is a poorly defined entity which has been 
described by Jalan et al as an acute deterioration in liver function over a period of two to 
four weeks in patients with previously well compensated CLD, caused by precipitating 
events such as sepsis, upper gastrointestinal bleed, ischaemia or superimposed liver 
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injury due to alcohol, hepatotoxic drugs or hepatitis virus infection.17 The role of viral 
hepatitis infections in the genesis of ACLF gains significance in countries like India 
which are hyperendemic for the enterically transmitted hepatotrophic viruses, hepatitis A 
virus (HAV) and HEV. 
 
Superinfection with HAV in CLD, particularly chronic hepatitis C associated liver 
disease has been shown to result in exacerbation of the underlying CLD with high 
mortality.18 Hence, HAV vaccination is advocated in patients with CLD in non endemic 
areas. Since HEV shares several epidemiological similarities with HAV including similar 
dynamics of disease transmission, superimposed HEV infection in patients with 
previously stable CLD merits critical attention as another preventable cause of severe 
liver decompensation. But the data on HEV superinfection in patients with underlying 
CLD is limited to a few small case series from the Indian sub-continent.11,12,13,14 There 
are unresolved issues regarding the behaviour of HEV in CLD. More data is needed to 
confirm its role in causation, persistence and final outcome of severe liver failure. A set 
of indicators of poor prognosis needs to be determined in this group of patients in order to 
define the best therapeutic strategies. Hence the present study was conceived in an 
attempt to better understand the clinical presentation, outcome and prognostic factors of 
acute HEV superinfection in CLD. 
 
 3
AIM 
1. To study the clinical profile and outcome of acute hepatitis E virus superinfection in 
patients with chronic liver disease. 
2. To identify factors affecting the outcome and determine their prognostic significance.     
 
 4
REVIEW OF LITERATURE 
Hepatitis E virus 
Historical background: 
Hepatitis E, previously known as enterically transmitted non-A, non-B hepatitis is an 
infectious viral disease with clinical and morphological features of acute hepatitis. The 
disease was first recognized as a distinct clinical entity in the 1980s, when sera from 
persons affected during a large waterborne epidemic of acute hepatitis during 1955-56 in 
Delhi, India and another epidemic in Kashmir, India tested negative for serological 
markers of acute hepatitis A and B.6,7,19 The occurrence of the first recorded epidemic of 
hepatitis E as late as 1955 and the infrequency of this disease in developed countries 
suggest that hepatitis E is a new emerging infectious disease.  
 
The first proof of the existence of a novel viral hepatitis agent was obtained in 1983, 
when virus like particles were detected by immune electron microscopy in faeces 
collected from a volunteer who was infected with faecal material from patients with 
suspected enterically transmitted non A, non B hepatitis.20 The disease was successfully 
transmitted to cynomolgus monkeys who excreted similar virus like particles in their 
faeces.20 The genome of this virus, now known as HEV21 was cloned in 199022 and fully 
sequenced shortly thereafter.23,24 
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Epidemiology:   
Regions of the world can be considered as hepatitis E disease endemic or non endemic 
regions based on the periodic occurrence of disease outbreaks. The geographical 
distribution of HEV is shown in figure 1. 
 
 
 
Figure 1: Geographical distribution of HEV 
The Indian subcontinent has faced many explosive outbreaks of the disease during the 
last four decades. The first and the best studied epidemic of HEV was reported in 1957 in 
which 29,000 people in Delhi were affected between December 1955 and January 1956.7 
Subsequently eight well studied epidemics (table I) have been reported from India with 
uniformly similar epidemiological features documented.25-30 
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 Year Location number Fatality% Aetiology 
1955 (Vishwanathan) Delhi 29300 0.22 (10.5%)# HEV** 
1960 (Bhattacharjee) Kharagpur 65 0.0 (NA) HEV* 
1961 (Dhamdhere) Aurangabad 865 0.34 (NA) HEV* 
1966 (Pattanayak) Siliguri 4287 0.09 (NA) HEV* 
1975 (Sreenivasan) Ahmedabad 2572 2.4 (NA) HEV** 
1978 (Khuroo) Kashmir 275 3.6 (75%)# HEV*** 
1979 (Tandon) Azamgarh 152 12.0 (39%)# HEV** 
1990 (Naik) Kanpur 79091 0.06 (NA) HEV** 
     
*   presumed aetiology (serological studies not carried out) 
* *   absence of serology for HBV / HAV 
* * *   positive serology for HEV 
#   mortality in pregnancy 
 
Several large epidemics of HEV have been observed in the developing countries of South 
East and Central Asia.3,6,7,8 Outbreaks have been documented in the Middle East and 
Northern and Western parts of Africa. Two small outbreaks were reported from Mexico, 
North America in the year 1986-87.31, 32  
 
HEV in disease endemic areas: 
In disease endemic regions the main epidemiological features which characterize HEV 
infection are as follows: 
 The HEV outbreaks are large,3,6,7,8 frequently affecting several hundreds to 
thousand persons in developing countries. Their time course varies from short 
lived single peaked outbreaks lasting a few weeks to prolonged, multimodal 
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epidemics lasting over a year. The outbreaks recur with a periodicity of 5-10 
years. 
 HEV infection accounts for a substantial proportion of acute sporadic hepatitis 
in both children and adults. In India, HEV infection accounts for 50-70% of 
all patients with sporadic viral hepatitis.4,5 Demographic and clinical features 
of patients with sporadic hepatitis E closely resemble those of epidemic 
hepatitis E.33  
 The fecal-oral route is the predominant route of transmission of epidemic 
HEV infection. Consumption of faecally contaminated drinking water has 
been incriminated as the cause of most reported outbreaks.6,7,8 Such 
contamination was due to backflow of sewage during floods,8,30 leakage of 
sewage drains contaminating corroded drinking water pipes7 and 
contamination of well water during rain.25,26,27 Food borne transmission has 
been postulated in some small outbreaks in China which occurred after 
community feasts.3  
 Person to person transmission of HEV infection is distinctly uncommon 
unlike other faeco-orally transmitted viral infections.7,34 Secondary attack 
rates among house hold contacts of HEV infected individuals are only 0.7-
2.2%7,35 in contrast to 50-75% in the case of HAV.36 
 Vertical transmission of HEV infection from mother to infant has been 
reported. Presence of HEV RNA was documented in five of six babies born to 
mothers with HEV infection in the third trimester.37 
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 The probability of nosocomial spread of HEV has been raised from South 
Africa where three health care workers who treated a patient with fulminant 
HEV infection, developed HEV infection six weeks later.38 
 There is no evidence of sexual transmission of HEV. 
 Parentral transmission of HEV has been documented in a recent study 
demonstrating the presence of HEV viraemia among healthy blood donors and 
transmission of infection to transfusion recipients.39 
 During epidemics, overall attack rates range from 1-15%. The highest attack 
rates is seen among young adults aged 15-40 years (3-30%) with relative 
sparing of children below 14 years.7,8,25,26,27,30 However in the sporadic setting, 
overt icteric hepatits has been well documented in children.40,41 During 
epidemics, anicteric hepatitis was found to be more frequent than icteric 
hepatitis.7,8,25,26,27,30 
 The male to female ratio among cases in most reports varies from 1:1 to 4:1. 
 HEV outbreaks are characterized by a particularly high attack rate and 
mortality (15-25%) among pregnant women, especially those in the third 
trimester.42,43 The frequency of acute liver failure has been significantly 
higher among pregnant women with HEV infection (10-22%) than the non 
pregnant women and men with icteric hepatitis(1-2%).7,8,25-27,30            
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HEV in disease non endemic areas: 
HEV accounts for less than 1% of acute viral hepatitis in non endemic regions and 
indigenous transmission of the virus in these areas appears to be rare. Isolated sporadic 
cases occur mainly among travellers to endemic regions.44,45 
 
Reservoirs of HEV: 
Subclinical HEV infections that maintain the presence of the virus in a population during 
inter epidemic periods may be a potential reservoir of HEV in endemic regions. In the 
experimental model of HEV infection in cynomolgus macaques, animals with HEV 
infection without biochemical evidence of liver injury excreted large amounts of the 
virus.46 However more data is needed to confirm the existence of continuous sub clinical 
circulation of HEV in endemic areas. 
  
Is Hepatitis E a zoonotic disease? : 
There is increasing evidence to implicate a zoonotic reservoir in the epidemiology of 
HEV which is as follows: 
 Discovery of swine HEV in pigs closely related to human HEV.47 
 Identification of genotype 3 & 4 human HEV isolates genetically identical to 
swine HEV isolates in the same geographic regions.48-57 
 Experimental cross-species infection of non human primates by swine HEV 
and of pigs by human HEV.58 
 Significantly higher anti HEV antibody prevalence in pig handlers than in age 
and geography matched controls.50,51,59,60 
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 Epidemiological link of sporadic cases of acute HEV to consumption of 
undercooked pork livers and detection of near identical HEV sequences from 
patients and packaged pork livers sold in local grocery stores.56,57 
 Existence of numerous other animal species positive for anti HEV antibodies 
(chicken, monkeys, cats , dogs, cattle and rodents).61,62,63 
 Discovery of avian HEV from bile samples of chickens with hepatitis 
splenomegaly syndrome in USA which is antigenically and genetically related 
to human HEV. Sequence data suggests that the virus causing big liver and 
spleen disease (BLSV) is also genetically related.63-66  
 Experimental cross-species infections of lambs and rodents by human HEV.62 
 Sporadic cases of acute HEV linked to consumption of raw deer meat.67 
 Significantly higher anti HEV antibody prevalence in humans with 
occupational exposure to animals than in controls.  
However the existing available data is insufficient to support the hypothesis of universal 
zoonotic origin of HEV. Moreover, genotypes 1 and 2 (responsible for large human 
epidemics) failed to induce infection in experimentally inoculated pigs.68  
 
Classification: 
HEV was originally classified within the Caliciviridae family but more detailed sequence 
analysis has resulted in its removal from this family and HEV is now classified as the 
type species of the genus Hepevirus, family Hepeviridae in the 8th ICTV report.69 
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Recent studies have greatly expanded the known diversity of HEV to include 4 putative 
genotypes.70 The prototype Burmese and related strains (Chinese) are classified as 
genotype 1, the divergent Mexican strain is classified as genotype 2, the swine HEV 
strain and closely related strains are classified as genotype 3 and distinct isolates from 
patients in China and Taiwan are classified as genotype 4. 
 
Structure and assembly: 
Virions of HEV isolated from bile or faeces are non enveloped, icosahedral particles of 
approximately 32-34 nm diameter,71 comprising a single viral protein, which 
encapsidates the single stranded positive sense RNA genome of approximately 7200 
nucleotides. Naked particles demonstrate some limited surface morphology but this is 
generally obscured by the use of antibody to complex virions for electron microscopy. 
(figure 2)     
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Figure 2: HEV particles from infected macaque faeces, complexed with acute phase 
patient serum. 
 
The 7204 nucleotide infectious cDNA clone of the SAR-55 strain of HEV described by 
Emerson and colleagues can be assumed to be full length.72 Most isolates of HEV are 
close to this length. The HEV genome contains a 7-methyl guanosine cap at the 5′ end,73 
essential for infectivity of RNA transcribed from cDNA.72 The viral RNA has short, 
highly conserved 5′ and 3′ untranslated regions (UTRs) of 25 and 68-75 nucleotides 
respectively which are likely to function in RNA replication and / or encapsidation. Three 
open reading frames (ORFs) organized as 5′ – ORF1 – ORF3 – ORF2 - 3′ with ORF3 and 
ORF2 largely overlapping, encode the viral proteins. The viral proteins (PORFs) may be 
translated from a set of sub genomic mRNA molecules. The PORF1 polyprotein contains 
domains consistent with replicative proteins. The PORF2 is the major capsid protein. The 
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function of PORF3 is unknown but it may have regulatory or replicative functions. Linear 
antigenic domains have been identified by peptide scanning through out each of the 3 
proteins. (figure 3) 
 
 
Figure 3: Genome organization and protein domains of HEV 
 
HEV virus like particles (VLPs) are smaller than the intact virus particle but Cheng and 
colleagues have used cryoelectron microscopy to give the first indications of HEV 
structure.75 A most striking feature of the VLP structure is the presence of dimeric 
subunits. Results of the cryoelectron microscopy analysis suggest that HEV VLPs are 
assembled as a T = 1 icosahedral particle containing 30 dimeric subunits of 50 kDa 
PORF2 with the potential to form an intact virion of the correct size with a T = 3 
arrangement of 90 dimeric subunits.75 
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Physico-chemical properties: 
Virions of HEV are much less stable than those of HAV, being sensitive to conditions 
such as CsCl and freeze thawing. This lower stability is likely to be a major factor in the 
low secondary attack rate for HEV. The single capsid protein is encoded by ORF2 
expected to yield a protein of 660 aminoacids (aa). However the capsid protein of 
authentic viral particles has not been characterized. 
 
Viral proteins: 
ORF1: Translation of ORF1 yields a polyprotein (PORF1) of approximately 186 kDa 
containing sequence motifs consistent with methyl transferase, papain like protease, RNA 
helicase and RNA dependent RNA polymerase (RdRp).23 Expression of PORF1 alone in 
HepG2 cells or in an invitro translation system failed to demonstrate any proteolytic 
processing into mature products. But in HepG2 cells transfected with a putative 
infectious cDNA clone of HEV, proteins could be detected76 leading to the conclusion 
that PORF1 processing can only occur in the context of the replication cycle. 
ORF2: The capsid protein PORF2 translated as a 660 aa protein includes a predicted N- 
terminal signal peptide.76 Deletion of the first 34 aa of PORF2 prevents translocation, 
glycosylation and surface expression, consistent with the predicted role of aa 1-22 as a 
signal sequence. PORF2 contains significant neutralizing epitopes in the region 578-607 
and a conformational immunodominant epitope spanning 394-468.77 Individual 
monoclonal antibodies to this immunodominant ORF2 epitope can block around 60% of 
total convalescent antibody binding to HEV VLPs.77  When PORF2 is expressed in insect 
 15
cells, it is cleaved into truncated forms, some of which have the ability to cell assemble 
into VLPs or subviral particles (SVPs)78 
 
ORF3: PORF3 may be translated from the same subgenomic RNA as PORF2 or from a 
“bicistronic” sub genomic RNA as ORF3 overlaps both ORF1 and ORF2.79 PORF3 is 
commonly reactive with patient antibody and may have regulatory functions in virus 
replication or assembly. 
 
Viral replication cycle: 
Due to the lack of practicable cell culture systems for HEV, knowledge of HEV 
replication is poor. The general outline of HEV replication is only inferred. HEV ingested 
in water or food reaches the liver via blood either via direct uptake of the inoculum 
through the gastrointestinal mucosa into the circulation or following one or more rounds 
of amplification in enterocytes. HEV particles interact with specific receptors on the 
basolateral domains of hepatocytes, leading to virus penetration and uncoating of the 
genome within the cell. The input viral RNA then serves as mRNA for the translation of 
PORF1 which is cleaved to yield the mature replicative proteins. The RdRp / helicase 
complex copies the input genome to yield full length negative strand RNA which in turn 
serves as a template for the transcription of positive strand RNA molecules and sub 
genomic mRNAs.80 These sub genomic mRNAs are translated to yield further molecules 
of PORF1, PORF2 and PORF3. PORF2 and new viral genomes assemble together into 
virions. Mature HEV is finally released from the cell mainly through the apical domains 
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of hepatocytes. The majority of the virus is excreted through the biliary system into the 
faeces to complete the transmission cycle. (figure 4) 
 
 
Figure 4: Putative replication cycle of HEV 
 
 
Pathogenesis: 
The pathogenesis of HEV infection is outlined based on data from human volunteers, 
patients and experimentally infected animals. The virus enters the host primarily through 
the oral route. In experimentally infected primates, HEV RNA appears in serum, bile and 
faeces a few days before the onset of ALT rise. HEV antigen in hepatocytes has been 
detected simultaneously with HEV identified in bile and faeces during the second or third 
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week after inoculation. This can be before or concurrent with the onset of ALT elevation 
and morphological changes in the liver.81 These findings suggest that HEV may be 
released from hepatocytes into bile during the initial highly replicative phase of infection 
before the occurrence of the more prominent histopathological changes in the liver. The 
onset of ALT elevation and occurrence of pathological changes in the liver generally 
correspond to the detection of anti-HEV in serum with decreasing levels of HEV antigen 
in hepatocytes. Both IgM and IgG antibodies have been detected in serum in assays using 
immunoreactive epitopes of ORF2 and ORF3. The IgM antibody level decreases rather 
precipitously reaching negligible levels in the early convalescent phase followed by high 
titres of IgG anti-HEV detected during convalescence. (figure 5)  
 
 
Figure 5: Pathogenetic events in HEV infection 
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IgM anti HEV appears in the early phase of illness, precedes IgG by a few days and 
disappears over 4-5 months. IgM anti HEV is positive in more than 90% of patients 
within 1wk to 2 months after the onset of  illness, in 50% at 4months, in 6% at 6-7 
months and absent by 8 months. IgG  anti HEV which is positive in more than 93% acute 
hepatitis, persists upto 24 months. 
 
Lymphocytes infiltrating liver in experimentally infected monkeys have a cytotoxic / 
suppression immunophenotype. Preliminary results of cellular immunity studies in HEV 
patients indicate that lymphoproliferative responses to HEV peptides from ORF2 and 
ORF3 regions occur in patients with acute HEV infection.82 Concordance of pathological, 
virological and serological findings in HEV suggests that the pathomechanism of the 
disease may be immune mediated rather than related to cytopathic effect of HEV. 
 
Clinical and pathological features of HEV:  
The incubation period of HEV ranges from 2-10 weeks. Clinical manifestations are 
similar to the acute hepatitis of other hepatitis viruses and encompass a wide spectrum of 
symptoms. Acute icteric hepatitis is the most common recognizable form of illness 
associated with HEV infection. The illness is usually insidious in onset and has an initial 
prodromal phase lasting about 1-4 days, with a variable combination of flu like 
symptoms, anorexia, nausea and vomiting, aversion to smoking, diarrhea, arthralgias, 
asthenia and a transient macular skin rash. These symptoms are followed in a few days by 
the appearance of jaundice. The onset of the icteric phase is frequently heralded by the 
darkening of the urine and may be accompanied by clay stools and itching. Physical 
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examination reveals a mildly enlarged, soft and slightly tender liver with a soft 
splenomegaly in a quarter of the patients.  
 
Laboratory test abnormalities include conjugated hyperbilirubinaemia and marked 
elevation of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
upto 10 times normal and mild rise in serum alkaline phosphatase. The liver enzyme 
elevation may precede the onset of symptoms by as much as 10 days and reaches a peak 
by the end of the first week. The liver function test values progressively come back to 
normal by 6 weeks, initially by decrease in the ALT ad AST followed by the bilirubin. 
The magnitude of transaminase elevation does not correlate well with the severity of liver 
injury. Some patients show mild leucopenia and relative lymphocytosis. The illness is 
usually self limiting and typically lasts 1-4 weeks.  
 
Histopathological features of acute HEV infection is similar to that of other forms of 
acute hepatitis, such as the presence of ballooned hepatocytes and acidophilic bodies, and 
focal and confluent hepatocyte necrosis with collapse and condensation of the underlying 
reticulum. Nearly half of the patients have cholestatic hepatitis, which is characterized by 
canalicular bile stasis and gland-like transformation of the parenchymal cells. In these 
patients, degenerative changes in hepatocytes are less marked and polymorphonuclear 
infiltration is prominent. In both forms, lobules and enlarged portal tracts show 
inflammatory infiltration. 
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No evidence of chronic hepatitis or cirrhosis has been detected among patients followed 
up clinically and with liver biopsies after an acute HEV hepatitis.83,84 A few patients have 
a prolonged cholestasis which resolves spontaneously in 2-6 months. The prognosis is 
good in these patients. 
 
HEV infected individuals may develop a non specific acute febrile illness without 
jaundice (anicteric hepatitis). In its most benign form, an asymptomatic HEV infection 
passes unnoticed. The exact frequencies of asymptomatic infection and of anicteric 
hepatitis are not known, but they probably far exceed that of icteric disease.  
 
In a small proportion of patients, disease is more severe and is associated with a sub-
acute hepatic failure (SAHF) or fulminant hepatic failure (FHF) that can be rapidly fatal. 
In patients with severe liver injury, a large proportion of hepatocytes are affected, leading 
to submassive or massive necrosis and collapse of the liver parenchyma. In disease-
endemic regions, hepatitis E is an important cause of FHF. HEV infection (alone or in 
combination with other hepatitis viruses) in India was responsible for 62% of adult 
patients and 40% of children with sporadic FHF.9,85,86,* It has also been suggested that 
FHF and SAHF may result from a combined infection with HBV and HEV.33,87 
 
There is also accumulating data on the impact of HEV superinfection in patients with pre-
existing CLD. Hamid et al14 in 2002, documented four cases of HEV superinfection and 
showed that it may lead to worsening of their clinical state. Subsequently, Jeyamani et 
al11 in 2004, retrospectively analysed nine cases of HEV superinfection and found that six 
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patients had died. The study also noted that six of the nine patients had Wilson’s disease 
as the aetiology of the underlying CLD and that seven patients had presented for the first 
time with decompensation. Monga et al13, over 18 months identified 10 patients with 
CLD and recent worsening (3 months) of hepatic function who were detected to have 
acute HEV infection and found that three patients had died. Seven of the ten patients had 
presented for the first time with decompensation. At the same time, Kumar et al12 did a 
prospective case control study with fourteen patients and documented two deaths. All had 
jaundice for less than one month at presentation as per inclusion criteria. Patients with 
significant ethanol intake and spontaneous bacterial peritonitis were excluded. The 
controls in this study were compensated cirrhotics.       
 
Diagnosis: 
One of the earliest tests used for identification of antibodies that react with HEV antigen 
was the fluorescent antibody blocking assay (FA). Although the FA assay enabled the 
serologic identification of HEV infection, it does not distinguish between recent and past 
infections and requires liver tissue substrate that contains HEVAg from HEV infected 
primates.81  
 
Enzyme immunoassays (EIAs) for the detection of IgM and IgG antibodies to HEV have 
been developed using recombinant HEV antigens expressed in E. Coli or baculovirus in 
insect cells and synthetic peptides corresponding to immunogenic epitopes of HEV.88,89 
Proteins encoded by all three ORFs of HEV are immunogenic but the ORF2 protein is the 
most immunogenic, the ORF3 protein is intermediate in immunogenicity and the ORF1 
 22
proteins are the least immunogenic. Three major epitopes found in the amino-terminal, 
central and carboxy-terminal regions respectively of the capsid protein have been 
reported. A major epitope is found in the carboxy-terminal region of the ORF3 gene 
product.90 The most highly conserved epitopes are those found in the capsid protein and 
thus this protein has been of most interest for the development of diagnostic assays. 
Antigens that contain the conformational neutralization epitope in the carboxy portion of 
the ORF2 protein are the most useful for serological studies.91 Antibodies to the ORF3 
protein diminish in titre more rapidly than antibodies to the ORF2 protein. Consequently 
antibodies to the ORF3 protein are useful for diagnosis of acute HEV infection.  
 
Recombinant peptides expressed from ORF2 and ORF3 of the Mexican strain of HEV 
were shown to react with sera collected from outbreaks of hepatitis E in Pakistan, Burma, 
Borneo, the USSR, and Somalia. The existence of these so-called type-common epitopes 
provided the basis for the development of immunoassays that broadly react with 
antibodies against different HEV strains.  Antigenic domains that contain strong IgG and 
IgM antigenic epitopes have been identified at the amino and carboxyl terminus of the 
ORF2 encoded proteins and have been shown to be more sensitive than ORF3 derived 
antigens, when used for the detection of IgM and / or IgG anti HEV.92 A highly 
conserved conformational epitope mapped to 267 aminoacids at the carboxyl terminus of 
the HEV ORF2 protein has been used in a sensitive and specific EIA format for the 
detection and quantification of both acute and convalescent phase HEV specific IgG.93 A 
synthetic gene encoding multiple linear immunodominant antigenic epitopes from ORF2 
and ORF3 regions has been synthesized, expressed as a protein and used in a solid phase 
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EIA.94 However recombinant proteins  are more sensitive than synthetic antigens for 
detecting IgG anti HEV.95 An analysis of IgM-specific EIAs indicated very high 
concordance when similar antigens produced in E. coli and insect cells were compared 
(concordance, 96.3%; kappa, 0.87).95 ORF2 based EIAs were found to be significantly 
more sensitive than ORF3 based EIAs and the sensitivity varied from 18-100% especially 
in non endemic countries. EIAs based on HEV specific artificial recombinant mosaic 
protein composed of antigenic epitopes from ORF-2&3 are commercially available.  
 
Current EIAs that measure IgM anti-HEV use the sandwich method of detection. 
Sensitivity is compromised when the corresponding IgG titers are disproportionately 
higher than those of the IgM  antibodies , since the IgG competes for binding sites on the 
antigen. High titers of Rheumatoid Factor interfere with the IgM assay. Anamnestic 
response has also been noted. Recently a capture EIA format was shown to be more 
sensitive in detecting IgM anti-HEV especially in the presence of high concentrations of 
IgG antibodies.96 In the IgM class capture system, competing IgG antibodies in the 
sample are eliminated at the beginning of the assay, thus enhancing the reaction between 
the IgM anti-HEV and the HEV antigen. The class capture method was more sensitive 
than the sandwich EIA when used to test clinical samples from two hepatitis E epidemics 
in Pakistan.  
 
A new Immunochromatographic test has been developed for the rapid detection of IgM 
anti-HEV within 2-3 min with a specificity of 97% and sensitivity of 96%. The newly 
developed test is a reverse-flow immunochromatographic test and uses immobilized 
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mouse anti-human IgM antibodies for capturing the IgM antibodies in the tested samples. 
The presence of the captured IgM antibody specific to HEV is detected by the colloidal 
gold-labelled anti-HEV monoclonal antibody 4B2 premixed with the recombinant protein 
of ORF2. 
 
Simultaneous detection of IgA and IgM antibodies to HEV was found to be highly 
specific for the diagnosis of acute HEV infection.97  
 
The detection of  HEV like particles and HEV RNA in faeces, bile, blood and liver has 
been accomplished by the use of immune electron microscopy (IEM) and the polymerase 
chain reaction (PCR). Several reverse transcriptase PCR assays (RT PCR) have been 
developed which can detect HEV RNA in faeces of most patients with acute hepatitis E 
during the initial few weeks.98 However RT PCR for HEV RNA is less suitable than 
serologic identification of IgM anti-HEV for routine diagnosis because HEV RNA is 
degraded during faecal shedding of the virus and the short viraemic phase usually occurs 
before the disease is clinically apparent. Hence, EIAs for the detection of antibodies to 
HEV are the most convenient, inexpensive and suitable assays for diagnosis and tracking 
the infection.   
 
Prevention strategies:  
Based on seroprevalence studies, it has been estimated, that a third of the world’s 
population has been infected with HEV. The poorer rural and urban populations of 
developing countries of Asia, the Middle East and Africa are at risk of contracting HEV 
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infection and would be candidates for a hepatitis E vaccine. Other groups at special risk 
of contracting HEV infection may be recipients of blood transfusions and patients on 
maintenance haemodialysis in regions where HEV is highly endemic.39, 99 Groups at 
special risk of severe hepatitis E include pregnant women and patients with CLD. In 
industrialized countries, the military, visitors to HEV endemic regions, swine handlers 
and those who eat raw or uncooked, contaminated food (pork and shellfish) are at higher 
risk of infection.  
 
In the absence of a viable HEV vaccine, improved sanitation and public hygiene and 
consumption of safe drinking water are the main stay of control of the disease.   
 
Passive immunoprophylaxis: 
Immunoprophylaxis trials of normal immune globulin in countries where HEV is 
endemic have not demonstrated statistically significant protection. The failure to 
demonstrate protection probably resulted from the relatively low titres of anti-HEV found 
in such globulin preparations. However direct demonstration of the protective efficacy of 
anti-HEV has come from studies in which, convalescent plasma or serum obtained from 
naturally infected patients or experimentally infected non human primates was infused 
into naive non human primates which were then challenged with HEV.100 The immune 
globulin protected the animals against hepatitis. Further evidence that antibodies protect 
against HEV come from studies of monoclonal antibodies that can neutralize HEV. Thus, 
if an immune globulin preparation with a sufficient high titre of anti-HEV can be 
prepared, it would be efficacious in preventing HEV when administered before exposure.      
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Active immunoprophylaxis : 
Among the HEV proteins, those encoded by ORF1 are non structural and not accessible 
to antibodies. These proteins are also among the least immunogenic of the virally 
encoded proteins of HEV.  The protein encoded by ORF3 is immunogenic but is 
relatively short lived and relatively genotype specific and the antibody to the ORF3 
protein does not neutralize HEV. Thus the protein encoded by ORF2, the capsid protein 
of the virus is the best candidate for a hepatitis E vaccine. It has a highly conserved 
sequence and antibody to it is long lived, cross reactive among diverse strains, neutralizes 
HEV in vitro and protects non human primates against HEV following challenge with 
virulent virus.95,100,80  
 
HEV ORF2 proteins for vaccine development have been expressed as recombinant 
proteins in a variety of systems but principally from E. coli as fusion proteins or insect 
cells from baculovirus vectors. The first reported candidate vaccine was a fusion protein 
expressed in E. coli from a truncated ORF2 gene. This 440 amino acid protein was 
designated trip E-C2.101 Another truncated ORF2 protein expressed in E. coli has proven 
to be useful both for serodiagnosis and as a candidate vaccine.102 This protein, truncated 
to amino acid 394 at its amino terminus and to amino acid 607 at its carboxy-terminus, is 
said to form homodimers that express a conformational epitope, but only in its dimerized 
form.  
 
Several candidate vaccines expressed from baculovirus vectors in insect cells have been 
studied. These vaccine candidates represent the various cleavage products derived from 
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the 72 kDa full length ORF2 protein when expressed from baculovirus in insect cells. 
They are: 
1. A 62 kDa protein encompassing amino acids 112-660 at the carboxy terminus of 
the protein.103 
2. A 55-56 kDa protein spanning aminoacids 112-607 of the ORF2 protein derived 
from a Pakistani strain. (genotype I of HEV)100 
 
Significant progress has been made in the development of DNA vaccines to HEV with 
better immune responses demonstrated to vaccination with ORF2 cDNA co-delivered 
with cytokine genes. A novel combination of two vaccination approaches using VLPs as 
vehicles for delivering heterologous DNA vaccine has been tried.104  
 
Although hepatitis E vaccines consisting of 62 kDa (Genelabs), or 56 kDa (NIH) ORF2 
proteins were both immunogenic and protective, the superior stability of the 56 kDa 
protein vaccine resulted in its selection by GlaxoSmithKline for clinical evaluation. The 
vaccine preparation contained purified 56 kDa capsid antigen derived from the HEV 
strain Sar-55 and expressed from baculovirus as recombinant protein in vaccine 
acceptable SF9 insect cells.105 A phase II / III trial of the vaccine was carried out by the 
US army in members of the Nepalese military. The vaccine appears to protect against all 
four recognized genotypes of human HEV. Thus only one vaccine will be needed for 
world wide protection. It appears that three doses of vaccine would be necessary for 
optimum protection and periodic booster immunizations may be necessary as the half 
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life of anti-HEV appears to be shorter than that of antibodies against other viruses. Thus 
a hepatitis E vaccine appears to be feasible in the near future.   
                   
Acute on Chronic Liver Failure:   
Acute on chronic liver failure remains an extremely poorly defined entity, largely 
because of the considerable heterogeneity in the mode of presentation. A working 
definition has been proposed by Jalan17 and associates: “Acute deterioration inliver 
function over a period of 2-4 weeks usually associated with aprecipitating event, leading 
to severe deterioration in clinical status, with jaundice and hepatic encephalopathy (HE) 
and / or hepatorenal syndrome (HRS)”. The numerous factors that may precipitate acute 
decompensation of CLD are divided into two groups. First, due to the effects of a known 
hepatotoxic factor such as superimposed hepatotrophic virus infection, drug reaction, 
ingesionof a hepatotoxin or excessive alcohol consumption. Second, liver injury due to 
precipating factors such as variceal bleed or sepsis. 
 
Prognosticating ACLF: 
The parameter best represented in prognostic models in CLD is the serum bilirubin. End 
organs, namely, the kidney and brain are frequently involved and determine outcome. 
The traditional Child Pugh score (CPS) not an ideal system because it ignores multi organ 
functioning and is not versatile in detecting changes on a day to day basis.106 The Mayo 
end-stage liver disease (MELD) score is a continous system and was found to be reliable 
for predicting outcome in patients with decompensated cirrhosis over a 3 month 
period.107 While the MELD score and the CPS are liver specific scores, scores which 
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have been validated among a general population in an intensive care setting have also 
been applied. These takes into account parameters representing respiration, coagulation, 
cardiovascular and central nervous systems. The 2 commonly used scores are Acute 
Physiology and Chronic Health evaluation (APACHE) II108 or the Sepsis-related Organ 
Failure Assessment (SOFA)109. Cholongitas et al, applied all these scores to a cirrhotic 
population admitted to an ICU with an aim to evaluate 6 week mortality and concluded 
that the MELD score and SOFA were similar in their discriminating ability to predict 
survival and better than APACHE II or Child Pugh scores.110         
 
Manifestations of ACLF: 
Liver : hyperbilirubinaemia, hypoalbuminaemia, coagulopathy and thrombocytopenia are 
invariably present. 
 
Circulatory changes : this holds the centre stage in the development of ACLF. Any 
alteration of hepatic perfusion, in a patient with CLD, be it generalized hemodynamic 
change like sepsis or GI bleed or a local alteration due to portal vein thrombosis leads to 
acute decompensation. Increased cardiac output, a dilated and hyporesponsive peripheral 
circulation, increased portosystemic shunting and a reduced renal blood flow are seen. 
These phenomena are thought to be secondary to a reduction in vascular responsiveness 
and desensitization to vasoconstrictors or to the effects of vasodilating factors, or both.  
 
Nitric oxide (NO), a profound vasodilator is a potential mediator in the 
hyporesponsiveness observed in CLD. NO is formed from L-arginine by calcium 
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dependant NO synthase (NOS).  Cirrhotics have elevated renin and angiotensin II levels 
due to splanchnic arterial vasodilatation, resulting in arterial underfilling of the renal 
vascular vasculature, leading to avid renal sodium and water retention inspite of an 
expanded total plasma volume. Induction of NOS is the likely explanation for the 
splanchnic arterial vasodilation. This has been borne out in studies on cirrhotic patients 
where inhibition of NOS corrected the altered systemic haemodynamics and improved 
renal function and sodium excretion.111 Inducible NOS (iNOS) in sepsis is dependant on 
cytokines like tumor necrosis factor α and interleukin I α and its activity is 
compartmentalized to the putrescent areas. It is possible that this compartmentalization, 
plays a role in the differential dilation of the splanchnic circulation with relative 
vasoconstriction of the renal and cerebral circulation in ACLF, especially when there is 
sepsis. Endothelial NOS (eNOS) is expressed by hepatic sinusoidal cells under basal 
conditions and has been shown to modulate portal pressure. 
 
Kidneys: HRS is characterized by severe renal hypo perfusion due to an increase in renal 
vascular resistance. It is one of the most dangerous complications of ACLF. Renal 
vasoconstriction is secondary to activation of the renin-aldosterone-angiotensin axis, 
sympathetic nervous system and increased endothelin-1 expressed in the hepatic 
sinusoids resulting in afferent arteriolar vasoconstriction. Compensatory mechanisms 
mediated by prostaglandins fail to maintain renal perfusion. This scenario is worsened in 
sepsis where there is worsening of vasodilatation. Excessive diuretics reduce renal 
perfusion further and non steroidal anti inflammatory drugs further prostaglandin 
production.  
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Brain: Hepatic encephalopathy (HE) is a potentially reversible neuropsychiatric 
syndrome that occurs in patients with significant liver dysfunction and is characterized by 
altered sleep cycle, varying degrees of confusion and disorientation, asterixis, 
hypereflexia and slowing of the dominant rhythm on electroencephalography. Ammonia 
remains central to the pathogenesis of HE. Recent studies in patients suggest cerebral 
oedema resulting in raised intracranial tension (ICT) can occur in CLD and that the 
pathophysiologic basis of HE in ACLF may be similar to that in acute liver failure (ALF) 
which has an inflammatory basis. Patients with sepsis syndrome had greater severity of 
encephalopathy and more raised ICT. A higher level of proinflamatory cytokines, 
possibly mediated by NO, has been noted with worse HE. 
 
Metabolic: Metabolic changes have a role to play in the worsening seen in ACLF. UGI 
bleed is one such scenario. In patients with cirrhosis, ingestion of erythrocytes produces a 
larger increase in ammonia than ingestion of whole blood or plasma.  The haemoglobin 
molecule is totally devoid of the branched chain amino acid (BCAA) isoleucine and large 
amounts of two other BCAAs, valine and leucine which have low biological value. 
Moreover leucine activates activates breakdown of BCAA producing ammonia and 
leading to a net catabolic state. 
 
Management:    
Prompt identification and treatment of precipitants when possible may improve short 
term mortality. Liver transplantation remains the only viable option in patients with 
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continued worsening decompensation or multi-organ failure. The role of liver assist 
devices as a bridge to transplant is controversial at present.    
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METHODOLOGY 
 
This was a retrospective study of patients who had acute Hepatitis E (HEV) infection 
with underlying chronic liver disease (CLD) who attended the hepatology outpatient 
services of the Christian Medical College Hospital, Vellore from January 2001 to June 
2006. 
 
Of  1768 patients who were clinically suspected to have HEV infection and underwent 
testing, 282 patients were ELISA IgM HEV positive. Of these, 47 patients had definite 
evidence of underlying CLD and were chosen for this study. (figure 6) 
 
Figure 6: identification of patients who had HEV infection and CLD  
 
Pts who underwent IgM HEV test 
1768
IgM HEV positive 
282
Acute 
218 (75%) 
Sub-acute 
12 (3.5%)
Acute on chronic 
47 (20%)
Fulminant 
5 (1.5%)
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Acute HEV infection was diagnosed using Immunoglobulin (Ig) M ELISA (Genelabs 
Diagnostics, Singapore), the assay detecting antibodies against recombinant proteins 
corresponding to open reading frames two and three of HEV. 
 
The diagnosis of underlying CLD was made by: 
(a) patients having a prior diagnosis of cirrhosis based on clinical, biochemical, 
endoscopic, ultrasonographic and histologic findings or 
(b) presence of a nodular, irregular liver with either collaterals on 
ultrasonography or at least grade II varices on upper gastrointestinal 
endoscopy or histology. 
Aetiological work up of CLD included HBsAg, anti-HCV, anti-nuclear antibodies 
(ANA), serum ferritin and a Wilson’s work up. This comprised of serum ceruloplasmin, 
24 hour urinary copper, liver biopsy, dry weight copper estimation by atomic absorption 
spectroscopy and slit lamp examination by an ophthalmologist to detect Kayer-Fleischer 
(KF) rings. 
 
Other causes of acute hepatic decompensation such as superimposed acute hepatitis B 
virus (HBV) or acute hepatitis C virus (HCV) infection, hepatocellular carcinoma, acute 
hepatic or portal vein thrombosis and recent hepatotoxic drug ingesion were ruled out.  
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The modified Child Pugh score (CPS)106 and Mayo end-stage liver disease (MELD)107 
score were calculated on all patients to prognosticate them. 
The MELD score was calculated as follows: 
3.8 x log (e) (bilirubin mg/dl) + 11.2 x log (e) (INR) + 9.6 log (e) (creatinine mg/dl)  
The CPS was calculated as follows: 
Measure 0ne point Two points Three points 
S. Bilirubin(mg/dl)  <2 2-3 >3 
S. Albumin(mg/dl)  >3.5 2.8-3.5 <2.8 
INR <1.7 1.71-2.20 >2.2 
Ascites None ↓ with diuretics Refractory 
Encephalopathy None Grade I-II Grade III-IV 
  
The clinical presentation, course in hospital and outcome of these patients were studied. 
Statistics:  
Data was reported as means with standard deviation or median with ranges (for continous 
variables) and as frequencies and percentages (for categorical variables). Univariate 
analysis was performed using the independent sample t test for continous variables which 
were normally distributed and the Mann Whitney test for continous variables which were 
not normally distributed and Chi square test for categorical variables. To identify factors 
that were independently associated with mortality, multivariate logistic regression 
analysis was performed. The discrimination ability of identified variables to predict the 
outcome of patients (either dead or alive) was evaluated by using the area under a 
receiver operating characteristic (ROC) curve. This has the true positive and false 
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positive rates on the vertical and horizontal axes respectively. In this analysis, a model 
with an area under the curve (AUC) between 0.7-0.8 is considered clinically useful and 
between 0.8-0.9 as having excellent diagnostic accuracy. As the AUC approaches 1.0, the 
model approaches 100% sensitivity and specificity. Data was analyzed by statistical 
software SPSS (Statistical Package for Social Sciences, release 11.0, standard version; 
SPSS Inc). A p-value ≤ 0.05 was considered statistically significant. All p-values were 2-
sided. 
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RESULTS 
 
 
Over five and a half years, there were 47 patients who had acute Hepatitis E virus 
infection (HEV) and underlying chronic liver disease (CLD). 35 (74%) were male and the 
mean age was 38 + 18 years (figure7). 
 
 
 
 
 
 
 
 
 
Figure 7: Demographic Profile 
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Only 9 (19%) patients had a prior diagnosis of CLD, the remaining patients presenting 
for the first time with decompensation. Wilson’s disease was the most common cause of 
CLD and seen in 12 (25%) patients. Table II shows how the diagnosis of Wilson’s 
disease was made in these patients. The other aetiologies (shown in figure 9) included 
Autoimmune 6 (13%), Hepatitis B virus infection 5 (11%), Ethanol 5 (11%) and 
Cryptogenic 10 (21%). Out of the remaining 9 (19%) patients, detailed aetiological 
evaluation remained incomplete at the time of death or discharge from hospital in 6, 
while 2 had cholestatic liver disease with secondary biliary cirrhosis and 1, extrahepatic 
portal vein obstruction with CLD.  
 
Table II - Diagnosis of Wilson's disease 
 
Age 
(years) 
Ceruloplasmin 
(60-120IU/L) KF ring 
24hr U Cu 
(<100µg) 
Liver 
biopsy 
Dry wt Cu 
(15-
55mg/Gm) 
8 Nil positive 590 cirrhosis -- 
7 17 positive 4561 -- -- 
18 73 negative 275 
Cu + 
bridging 
fibrosis 
-- 
14 6 negative 540 -- -- 
34 112 positive -- 
Cu + 
bridging 
fibrosis 
-- 
36 70 negative 149 Cirrhosis 512 
18 11 positive 900 Cirrhosis -- 
41 20 -- 87* Cirrhosis 1000 
7 63 -- 2527 Cirrhosis -- 
21 12 -- 414 
Cu + 
bridging 
fibrosis 
-- 
21 19 positive 78* cirrhosis 171 
7 91 positive 907 -- -- 
 
* inappropriate sample collection 
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Figure 8: Aetiology of CLD 
 
Forty-eight (98%) patients presented with jaundice with a median duration of 60(240) 
days. 39(83%) patients also had ascites with a median duration of 15(90) days. The 
median duration between onset of jaundice and development of ascites was 31(232) days. 
The median duration of the hospital stay was 11(59) days. 
 
Biochemical investigations are listed in table III. Only 1 out of 38 (3%) patients tested 
positive for acute hepatitis A co-infection. 
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Table III - Biochemical parameters 
 
Variable Mean + Standard deviation 
Total bilirubin 16.9 +10.2 mg/dl 
Serum albumin 2.3+0.5 mg/dl 
AST 248+162 IU/ml 
ALT 175+225 IU/ml 
SAP 212+156 IU/ml 
PT - INR 2.1+1.4 
Creatinine (at admission) 1.1+0.8 mg/dl 
Creatinine (highest) 1.7+1.5 mg/dl 
IgM Anti HAV (N= 38) 1 
 
Upper gastrointestinal endoscopy was performed in 37 (79%) patients. As shown in 
figure 9, 16 (43%) patients had varices which were grade II or more (large), while 9 
(24%) patients did not have any varices. On ultrasound examination, 29 (62%) patients 
had a normal liver size, while the remaining 18 (38%) patients either had a symmetrically 
shrunken liver or a significantly altered lobe ratio.  A liver biopsy was performed in 20 
(43%) patients with diagnostic intent; the transjugular method being the preferred route in 
17 (85%) patients. One biopsy was a surgical specimen from an explanted liver during an 
orthotopic liver transplant while another was a post mortem specimen. 
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Figure 9: Oesophageal varices on endoscopy (performed in 74%) 
 
The complications that the patients developed during their hospital stay are listed in table 
IV. 21 (45%) patients had hepatic encephalopathy. The grades of encephalopathy are 
shown in figure 10. 14 (30%) patients had spontaneous bacterial peritonitis, while 11 
(23%) patients developed other infections like urinary, respiratory and skin (figures 11 
and 12). Four patients had culture proven bacterial sepsis, the focus of which was not 
apparent. 
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Table IV – Complications 
 
Encephalopathy 21 (45%) 
SBP 14 (30%) 
GI Bleed 7 (15%) 
Renal Failure 20 (43%) 
Infection 25 (53%) 
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Figure 10: Grades of encephalopathy 
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Figure 11: Infections 
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Figure 12: foci of infections 
 
Mortality   
The overall mortality was high, 14 (30%) patients having died and 6 (13%) having been 
discharged in a terminal state (figure 13). These patients were also included in the 
mortality analysis. Of the 12 females and 35 males, 8 (67%) and 12 (34%) died 
respectively (p = 0.05) (figure 14). Figure 15 shows the mortality according to the various 
aetiologies of CLD. The duration of jaundice at presentation or the duration between the 
onset of jaundice and development of ascites had no bearing on the outcome (p = 0.30 
and 0.43 respectively). On ultrasound examination, of the 29 (62%) patients with normal 
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liver size and 18 (38%) with shrunken liver, 9 (31%) and 11 (61%) died respectively (p = 
0.04). 
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Figure 13: Outcome 
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Figure 14: Mortaliy based on sex 
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Figure 15: Mortality base on aetiology 
Factors associated with mortality:  univariate analysis 
On univariate analysis, the presence of renal failure and hepatic encephalopathy were 
significantly associated with mortality (p < 0.001 and p = 0.02 respectively). Of the 
biochemical variables, serum bilirubin (p < 0.001), serum creatinine (p < 0.001), serum 
sodium (p < 0.001) and the MELD score (p < 0.001) had prognostic value. The factors 
affecting mortality are listed in table V(a) and table V(b).   
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Table V(a) - Factors affecting mortality (univariate) 
 
Variable Alive (N=27) Dead (N=20) p value 
Age (yrs) 34+17 42+18 0.13 
Duration of jaundice (days) 60(240)* 30(239) 0.30 
Jaundice to ascites interval 
(days , N=39) 30(224)* 55(231) 0.24 
Shrunken liver on USG 7 (26%) 11 (55%) 0.04 
Encephalopathy 8 (30%) 13 (65%) 0.02 
SBP 8 (30%) 5 (25%) 0.73 
Infections 12 (44%) 13 (65%) 0.16 
Renal failure 4 (15%) 16 (80%) < 0.001 
 
* median (range) 
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Table V(b) - Factors affecting mortality (univariate) 
 
Variable Alive (N=27) Dead (N=20) p value 
Bilirubin (mg/dl) 13.3+9 21.8+10 < 0.001 
S. albumin (g/dl) 2.2+0.6 2.3+0.4 0.80 
ALT (IU/ml) 158+108 198+326 0.55 
PT - INR 1.9+0.7 2.5+1.9 0.15 
Creatinine (mg/dl) 0.9+0.4 2.6+1.8 < 0.001 
Sodium (mg/dl) 135+5 127+10 < 0.001 
MELD 20+7 32+10 < 0.001 
Modified CPS 11+2 12+2 0.07 
 
 
 
Factors associated with mortality: multivariate analysis 
On multivariate logistic regression analysis, comparing the MELD score and serum 
creatinine separately with serum sodium and encephalopathy, the MELD score and serum 
creatinine were independently associated with mortality (p < 0.001). 
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Prognostic factors associated with mortality: receiver-operating characteristic (ROC) 
curves 
Based on the area under the ROC curves, serum creatinine had the best discriminative 
accuracy for mortality (AUC = 0.86), followed by the MELD score (AUC = 0.84) and 
serum bilirubin (AUC = 0.73) (Figure 16). Table VI shows the sensitivity and specificity 
at the cut off points of the above three variables as predictors of mortality.    
       
 
Table VI - Predictors of mortality 
 
Variable Value Sensitivity (%) Specificity (%) 
Creatinine 1.3 mg/dl 80 82 
MELD 23.5 80 78 
Bilirubin 16.8 mg/dl 80 74 
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DISCUSSION 
 
 
This study confirms the already existing but sparse data that acute HEV superinfection in 
patients with chronic liver disease (CLD) produces severe decompensation and is 
associated with a high mortality rate. 
 
The male to female ratio in this study was 4 : 1 in accordance with most other 
reports.6,8,43 It is unclear whether this reflects a greater frequency of exposure among men 
due to the prevalent social mileu in India or a true difference in susceptibility. 
 
The commonest aetiology of underlying CLD in this study was Wilson’s disease. The 
prevalence of Wilson’s among children in India varies from 7.5–10%.112,113 In a study of 
liver diseases in childhood in which six medical colleges with organized paediatric 
gastroenterology and hepatology services participated, metabolic liver diseases 
constituted 8-43% of the reported CLD, of which Wilson’s was the commonest metabolic 
cause of CLD.114 The seroprevalence of HEV infection steadily increases from 
childhood, being 0-9% in the first decade and peaking at 40% between 16-25 years, after 
which it plateaus.115 The seroprevalence of HEV infection in patients with CLD varies 
between 17-56% with the maximum prevalence being between the third and fifth 
decade.11,14,116 Only 3 of the Wilson’s patients in this study were over the age of  21 
years.  
 
This begs the question : are patients with Wilson’s disease any more prone to the hepatic 
injury produced by HEV or is this simply a reflection of the higher chance of developing 
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HEV infection in an age group where Wilson’s is the commonest metabolic cause of 
CLD ? 
 
Acute liver failure is one of the myriad presentations of Wilson’s and this presentation 
has been reported in a patient with acute HEV infection and co-existent Wilson’s.117 The 
majority of our patients presented for the first time with decompensation, very similar to 
the findings of Monga et al where seven out of ten patients were detected to have CLD 
during the current admission.13 This underlines the importance of having a high index of 
suspicion for a superadded viral infection in a similar clinical setting. It is noteworthy 
that one patient in this study who presented for the first time with Wilson’s disease and 
acute HEV infection underwent a live related orthotopic liver transplant successfully and 
is currently doing well. 
 
Acute on chronic liver failure (ACLF) has been defined for us by Jalan and associates as 
an acute deterioration in liver function over a period of two to four weeks in a person 
with previous liver disease, usually associated with a precipitating event.17 Indeed Kumar 
and colleagues, in their prospective case-control study of 14 CLD patients with acute 
HEV infection had included only cases with jaundice of less than four weeks duration.12 
However it was seen here that the median duration of jaundice at presentation was double 
that at eight weeks. Therefore the pre-occupation with time frames in defining the 
syndromes associated with liver failure, particularly ACLF, may warrant revision. More 
importantly, the duration of jaundice had no bearing on the outcome. 
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Only one of the patients had co-infection with the hepatitis A virus. This is hardly 
surprising considering that the seroprevalence of HAV infection in patients with CLD in 
an endemic region like India is 99%.11 
 
As expected, a shrunken liver on ultrasound examination, an indicator of advanced 
cirrhosis was associated with mortality in this study. What was interesting however was 
the fact that more than 60% of the patients had normal sized livers and it was a liver 
biopsy, performed in 43% which helped clinch the diagnosis of underlying cirrhosis. This 
is especially important when the clinical scenario does not allow differentiation between 
ACLF and sub-acute hepatic failure (SAHF), an entity defined by Tandon et al, where the 
interval between the onset of jaundice and hepatic decompensation in the form of hepatic 
encephalopathy and / or progressive ascites is more than four weeks and less than twenty-
four weeks.118 This differentiation may have significant prognostic and therapeutic 
implications given the potentially reversible nature of ACLF if precipitants can be 
controlled. 
 
The current study is the largest documented series of patients with CLD and serological 
evidence of acute HEV infection. The disproportionately high mortality that was 
observed is similar to what has been seen earlier from the Indian sub-continent, albeit in 
small case series. Hamid et al initially reported 4 cases of HEV superinfection with 1 
death after which Jeyamani et al (6 deaths out of 9 cases), Kumar et al (2 out of 14) and 
Monga et al (3 out of 10) reported similarly in quick succession.14,11,12,13 These studies 
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however failed to delineate the factors responsible for this dismal scenario, nor did they 
indicate how severe the decompensation was with respect to short term prognosis. 
 
The modified Child Pugh score (CPS)106 and Mayo end-stage liver disease (MELD) 
score107 are liver specific prognostic scores. The MELD score has been validated for 
three month survival in cirrhotics and is currently used in donor liver allocation 
systems.119 The Acute Physiology and Chronic Health Evaluation (APACHE II)108 and 
Sequential Organ Failure Assessment (SOFA)109 are ICU specific prognostic scores 
developed from general ICU populations, both providing clinical information on organ 
dysfunction. In a recent study comparing general and liver specific prognostic scores and 
evaluating six week mortality in 312 cirrhotics admitted to the ICU, MELD was similar 
to SOFA, both being better predictors of mortality than APACHE II or CPS.110 In the 
same study, a MELD score of 22 had a sensitivity of 81% and specificity of 69% at 
predicting mortality.  
 
In this study, the presence of renal failure and hepatic encephalopathy, both indicators of 
failing organ systems and hyponatremia were factors associated with mortality on 
univariate analysis. The MELD score and serum creatinine were independently 
associated with mortality. Alessandria et al120 and Schepke et al121 have reported 
similarly where MELD and hepato-renal syndrome I (HRS I) independently predicted 
survival in cirrhotics. A serum creatinine of > 1.5 gm/dl had an adverse impact on 
prognosis.120 Schepke and associates have also demonstrated that HRS is associated with 
a worse prognosis than kidney dysfunction due to other causes including renal 
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parenchymal disease, volume depletion and infections. In this present study, serum 
creatinine had the best discriminative accuracy for mortality (AUC = 0.86) followed by 
MELD (AUC = 0.84) and serum bilirubin (AUC = 0.73). A serum creatinine of 1.3 and a 
MELD score of 24 had a sensitivity and specificity of around 80% for predicting 
mortality. Thus the development of renal failure in cirrhotic patients indicates a 
catastrophic reduction in survival probability, such that it is the predominant factor in end 
stage cirrhosis.     
 
This study assessed for the first time MELD scores in patients with acute on chronic liver 
failure, the precipitating event being a superimposed hepatotrophic viral infection. The 
MELD score is liver specific and contains surrogate variables related to more than one 
organ dysfunction. It proved to be an accurate prognostic indicator of patient mortality in 
the present study. 
 
The Paediatric end-stage liver disease (PELD) score which additionally incorporates 
growth failure and age was proposed as a model for improving liver allocation in children 
awaiting transplantation122 and has been validated as a predictor of post transplant 
survival.123 This score was not applied to the 7 children in this study, because the aim was 
to obtain a comparative score between this small sub-group and the rest of the adult 
patients. 
 
This study is not without its limitations. No comparisons were made with other forms of 
ACLF. Also, being retrospective in design, the study could not provide information on 
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the true incidence of HEV infection among patients with CLD. For this, a prospective 
case-controlled follow up study of patients with definite CLD in a HEV endemic region 
is required. 
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CONCLUSIONS AND RECOMMENDATIONS 
1. Acute HEV superinfection in patients with underlying CLD produces severe  
decompensation and is associated with a high mortality rate. 
2. The MELD score and serum creatinine are the most important and accurate 
prognostic indicators of patient mortality in this setting. 
3. A serum creatinine of 1.3 mg/dl and a MELD score of 24 were 80% sensitive and 
specific in predicting mortality.  
4. The duration of jaundice did not affect the outcome. 
5. Infections, including spontaneous bacterial peritonitis did not worsen the 
outcome. 
6. A possible association between Wilson’s disease and HEV superinfection requires 
further in depth study 
7. A liver biopsy is crucial in conclusively establishing a diagnosis of underlying 
cirrhosis and must be performed when the clinical picture is unclear. 
8. Obsessive attention to prevention and early aggressive management of treatable 
causes of renal failure may aid in improving the current short term mortality rates 
9. In a developing country like India, with limited resources, one is duty bound to 
emphasize the importance of safe drinking water to all patients, especially those 
with CLD, in preventing HEV infection. 
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PROFORMA (page i) 
Name  : 
Age  :  
Sex  : 
Hospital Number: 
 
Jaundice: Present /Absent  Duration of Jaundice:         (Days) 
Ascites: Present / Absent             Duration of Ascites:    (Days) 
Duration of Jaundice to ascites:  (days) 
 
Aetiology of Chronic liver disease (Please circle):  Hepatitis B 
           Hepatitis C 
           Ethanol 
           Autoimmune 
                    Wilson’s 
           Cryptogenic 
            Others 
Known case of Chronic liver disease: Yes/No 
 
Course: Alive / Dead / Discharged against medical advise (DAMA) 
 
Encephalopathy: Prevent/Absent 
Grade of encephalopathy: 0 / 1 / 2 / 3 / 4 
Spontaneous bacterial peritonitis: Present / Absent           
GI Bleed: Present / absent 
 
PROFORMA (page ii) 
 
Varices: No / small varices (<Gr II) / Large varices (>Gr II) / not done  
Infection (Other than SBP): Present / Absent 
Type of Infection: Urinary:    Present / Absent 
(Culture proven)  Respiratory:  Present / Absent 
    Skin:    Present / Absent 
    Sepsis:   Present / Absent 
 
Liver size on Ultrasound: Normal or Enlarged / Shrunken or asymmetric 
Liver Biopsy Done: Yes / No 
Route of Liver biopsy: Transjugular / Percutaneous / Surgical  
Total Bilirubin (mg/dl) : 
Serum Albumin: (mg/dl): 
SGOT (IU/ml): 
SGPT (IU/ml): 
ALP (IUml): 
PT (INR): 
S. Creatinine (at admission): 
S. Creatinine (highest): 
S. Sodium (at admission): 
S. Sodium (Highest): 
IgM anti HBV:  Done / Not done  
         Positive / Negative  
     Child Pugh Score: 
Meld Score: 
Follow up (days) (if available):   
